Genome Explorations Inc. was founded by Dr. Divyen H. Patel to provide academic and industrial institutes with a 'Complete Solution' for Genotyping, Gene expression and miRNA profiling. Dr. Patel initiated and ran the Affymetrix GeneChip processing core at St. Jude Children's Research Hospital. The finding's from one of the many studies conducted through his core was described in a seminal study on the cover of Cancer Cell (Cancer Cell Vol. 1 133-143 March 2002). The study showed for the first time that microarray technology could be used to enhance diagnosis of pediatric leukemia and could also be used to evaluate prognostic outcome. The extensive experience gained through working with scores of investigators on many varying projects has made Genome Explorations Inc. the number one choice for Investigators worldwide.

Oxford Gene Technology Ltd. owned company was founded in 1995 by Professor Sir Edwin Southern. Oxford Gene Technology (OGT) provides microarray products and services that enable clinical research and molecular diagnostics in academic, hospital, and government research laboratories. One of its key business areas, licensing, gives companies access to its intellectual property that covers microarrays, genomics, and electrochemistry. OGT's research focuses on developing novel microarray technologies for new applications such as drug discovery and disease diagnosis.

Ricerca Biosciences LLC company provides one stop shopping of pharmacology and toxicology, medicinal chemistry, drug substance synthesis, and preclinical and clinical development for small to medium pharmaceutical companies looking to bring drugs to market. The contract research organization (CRO) also offers regulatory filing and report writing services. Ricerca Biosciences provides expanded services through partnerships with companies such as Bicoll Group, Latitude Pharmaceuticals, and Xcelience Formulation Development.

Nile Therapeutics, Inc. company was founded in 2005 and is based in San Mateo, California. Nile Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics for the treatment of cardiovascular disease and other areas of unmet medical needs. The company focuses on developing its lead compound, CD-NP, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure. CD-NP was designed to reduce symptoms of dyspnea in heart failure patients through both a reduction in intracardiac pressure and an improvement in renal function. Nile is also developing CU-NP, a novel, rationally designed natriuretic peptide.

BioDelivery Sciences International, Inc. company was founded in 1997 and is based in Raleigh, North Carolina. BioDelivery Sciences International, Inc. operates as a specialty pharmaceutical company in the United States. Its patented drug delivery technologies include BEMA drug delivery technology and Bioral cochleate drug delivery technology. The company, using its drug delivery technologies, develops formulations of pharmaceuticals aimed principally at short term acute conditions occurring in patients, primarily in the areas of pain and fungal infections. Its lead product is ONSOLIS, a treatment for pain in opioid tolerant patients with cancer. BioDelivery Sciences licensed the commercialization and distribution rights for ONSOLIS to Meda AB.BioDelivery Sciences Company's products/formulations also include BEMA Buprenorphine, which is under preparation for phase 2 for moderate to severe and acute pain. Its lead Bioral formulation is an encochleated version of Amphotericin B, an anti-fungal treatment for systemic fungal infections. The company also has a Bioral formulation, which is in initial in vitro studies for the intranasal administration of Amphotericin B to treat chronic rhinosinusitis. BioDelivery Sciences has a research collaboration and licensing agreement with the Drugs for Neglected Diseases initiative (DNDi) to develop Bioral Amphotericin B for the treatment of neglected diseases, such as leishmaniasis and Chagas disease.

GTC Biotherapeutics develops, produces, and commercializes therapeutic proteins through transgenic animal technology. ATryn®, our recombinant form of human antithrombin, is the first transgenically produced protein to be approved anywhere in the world, having recently been approved by the European Commission for the prophylactic treatment of deep vein thrombosis in patients with hereditary antithrombin deficiencies that are undergoing surgical procedures. ATryn® is produced in the milk of goats developed using micro-injection technology to incorporate a human antithrombin transgene. In addition to ATryn®, GTC is developing additional recombinant forms of therapeutic proteins normally found in human blood plasma as well as monoclonal antibodies. These products have potential applications in hematology, oncology, and autoimmune diseases.

Trius Therapeutics is an early-stage biopharmaceutical company developing antibiotics to treat life-threatening bacterial infections. Torezolid phosphate, its most important drug in development, is an IV- and orally-administered antibiotic with a potential to treat antibiotic-resistant strains of staph infections, known as MRSA (methicillin-resistant Staphylococcus aureus). Until the company is able to sell torezolid phosphate to hospitals and other health care providers, the company is primarily funded by government grants, research contracts, and collaboration agreements. The company filed for an initial public offering in November 2009.

Rowett Research Services (RRS) will supply the technology, thanks to its research parent, the Rowett Institute. It will even throw in marketing services and project management. All RRS needs are companies interested in commercializing new ideas and products. Its primary focuses are nutrition issues and outpatient health care studies, such as antimicrobial agents and antioxidants. Founded in 1988, RRS works with public and private partners in the pharmaceutical, biotechnology, food, and agricultural industries to bring the research underway at the Rowett Institute to the marketplace.

Sanofi Pasteur helps you guard against getting sick in the first place. The company is the US vaccines division of French drugmaker Sanofi-Aventis. It makes vaccines that protect against such infectious diseases as influenza, polio, and meningitis. Some of its top sellers are flu vaccines, childhood combination vaccines, and adult booster shots. It also makes travelers' vaccines that keep globetrotters safe from typhoid, cholera, yellow fever, and the like. Projects in development include improved vaccines for influenza, preventative vaccines for HIV and dengue fever, and therapeutic vaccines for cancer.

TargeGen is developing small molecule therapeutics to treat cancer and cardiovascular disease. The development-stage firm's lead drug candidate, TG 100-115, could prevent complications after heart attacks. Other therapies in TargeGen's pipeline include a potential treatment for colorectal cancer, non-small cell lung cancer, and macular degeneration, an eye condition that often leads to blindness. The biotech company had been eying an IPO but opted in mid-2005 to stay private and took on an additional round of venture capital financing to fund trials of TG 100-115.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.